S8.

Pathological response criteria following neoadjuvant therapy according to College of American Pathologists (CAP)/The National Comprehensive Cancer Network (NCCN) Guidelines

Diagnostic criteria	Tumor regression grading
1) Tumor regression grading can only be assessed in primary tumors, but not for metastatic lesions; 2) therapeutic evaluation depends on the residual tumor cells. The presence of tumor-free keratin or mucus lake after neoadjuvant therapy should not be considered as residual tumor; tumor-free keratin or mucus lake in lymph nodes should not be regarded as tumor metastasis.
No viable cancer cells	0 (total response)
Single cells or rare small groups of residual cancer cells	1 (moderate response)
Residual cancer outgrown by fibrosis	2 (mild response)
Rare tumor cells regression or absence of any tumor cells regression; extensive residual cancer cells	3 (poor response)